Clinical trial Recruiting at 1 site Observational Ages 21 and up

Evaluating the safety of Terahertz scanning on corneas

Official title: Evaluation of the Safety of Terahertz Scanning System on Corneas: Phase I Trial

Run by Singapore Eye Research Institute · NCT06967792 · Data updated 2026-11-12

This study is testing if a new Terahertz scanning system is safe to use on the corneas of people who can't see but have healthy eyes.

More Corneal Diseases trials

Quick facts

Study typeObservational
Ages21 Years and up
SexAll
Enrollment5 (estimated)
SponsorSingapore Eye Research Institute
Academic / other
Drugs / interventionsradiation
Locations1 site (Singapore, Singapore)
StatusRecruiting
StartedApril 1, 2024
Main results expectedDecember 31, 2025
Study endsApril 30, 2026
Registry record updatedMay 16, 2025
Trial IDNCT06967792 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are individuals aged 21 and older with at least one functionally blind eye that has a healthy cornea.

Probably not a fit

Patients with a history of major corneal surgery, active inflammation, or systemic diseases affecting the ocular surface may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the safety of the Terahertz (THz) scanning system in individuals with non-seeing eyes but healthy corneas. Participants will undergo THz scanning, followed by comprehensive eye examinations at various intervals to monitor visual acuity, corneal health, and nerve status. The study hypothesizes that the THz scanning system is safe for application on the human cornea, which is crucial for understanding corneal hydration and preventing conditions like corneal opacification. The findings could provide insights into non-invasive monitoring techniques for corneal diseases.

Why it matters

Potential benefit: If successful, this study could lead to safer and more effective monitoring of corneal diseases, potentially preventing irreversible blindness.

How similar studies have gone: While the use of Terahertz imaging is a novel approach in this context, similar imaging techniques have shown promise in other areas of ocular health.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Be at least 21 years of age
* Regardless of gender (Male/Female)
* Regardless of race (Chinese/Malay/Indian/Eurasian/Others)
* Willingness and ability to follow all instructions and comply with study schedule for study visit
* Have at least 1 eye (Study eye) that is deemed functionally blind but contain healthy corneas
* Ability to hold face sufficiently stable to undergo necessary scans
* Best Spectacle Corrected Visual Acuity (BSCVA) in the study eye of hand motion or worse

Exclusion Criteria:

* Pregnant/Breast-feeding women
* Eyes with previous major surgery on the cornea such as corneal transplantation, refractive surgery, corneal cross-linking procedure
* Eyes with previous infectious keratitis
* Eyes with long-term use of glaucoma eye drops
* Eyes with known moderate or server meibomian gland dysfunction
* Eyes with active inflammation or infection, or chronic ocular surface inflammation
* Systemic diseases that affect the ocular surface, such as systemic autoimmune diseases

Where it's running

  • Singapore National Eye Centre
    Singapore, Singapore, Singapore
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.